|
|
News Breaks | | | | February 5, 2013 | | 07:06 EDT |  | HOLX | Hologic shares may become attractive at $20 level, says Cantor
After Hologic provided in-line FY13 EPS guidance, Cantor believes that the guidance will be very difficult for the company to beat, given its comment that 3D tomo is unlikely to exceed previous expectations this year. The firm thinks the company faces a number of near-term challenges and maintains a Hold rating, but the firm would "become more constructive" on the stock if shares reach the $20 level. | |
|
News For HOLX From The Last 14 Days Check below for free stories on HOLX the last two weeks. |
|
|
| June 13, 2013 | | 09:38 EDT | | HOLX | Hologic estimates lowered below the Street at SunTrust
SunTrust lowered Hologic estimates below the Street due to 3D Tomo adoption concerns following cautious survey results. Share are Reduce rated. | | | June 6, 2013 | | 15:11 EDT |  | HOLX | QIAGEN affirms FY13 view after Quest Diagnostics, Hologic strike deal
QIAGEN (QGEN) said its full-year earnings view will not be changed following an announcement that Quest Diagnostics (DGX) and Hologic (HOLX) reached a supply agreement. WHAT'S NEW: Earlier today, Quest Diagnostics and Hologic announced a non-exclusive agreement for Quest to more broadly offer Hologic's APTIMA family of testing products. Hologic's APTIMA line includes FDA-approved or cleared assays for HPV, HPV genotyping, chlamydia, gonorrhea and trichomonas vaginalis. WHAT'S NOTABLE: Following the announcement, QIAGEN, which competes with Hologic in the diagnostic product space, said that a "U.S. reference laboratory customer" of its products made public a deal to consolidate the purchase of products used for women's health diagnostics with a competitor supplier. QIAGEN said the customer would continue to offer its HPV-related products as well. QIAGEN said that it saw no need to revise its full-year 2013 guidance based on the development. The company also noted that sales related to this development represent less than 2% of the company's anticipated 2014 sales, and HPV screening in the U.S. is expected to represent less than 10% of the company's 2014 total net sales. PRICE ACTION: Hologic advanced following news of its agreement with Quest, and its shares are up over 2% in afternoon trade. QIAGEN shares are off their best levels, but still higher by about 0.5%. | | | 13:08 EDT | | HOLX | Quest Diagnostics, Hologic in strategic alliance for women's health
 Subscribe for More Information | |
|
|
|
|
|
|
